

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
650 daily bars · split adjusted
Current price $5.16
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| May 26, 26 |
Daily · Wilder smoothing
| JP Morgan |
| maintain |
| Neutral |
| Neutral |
| Nov 18, 25 | JP Morgan | downgrade | Overweight | Neutral |
| Feb 11, 25 | JP Morgan | maintain | Overweight | Overweight |
| Sep 20, 24 | JP Morgan | maintain | Overweight | Overweight |
| Aug 20, 24 | JP Morgan | maintain | Overweight | Overweight |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.15 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 70.74 | Oscillator | Neutral |
| Williams %R (14) | -32.22 | Oscillator | Neutral |
| MACD (12, 26, 9) | 0.03 (Hist 0.00) | Oscillator | Strong Buy |
| Average Directional Index (14) | 23.93 (+DI 21.2 / -DI 36.4) | Trend | Sell |
| EMA 20 | 5.21 | MA | Sell |
| SMA 20 | 5.17 | MA | Sell |
| EMA 50 | 5.18 | MA | Sell |
| SMA 50 | 5.20 | MA | Sell |
| SMA 200 | 5.12 | MA | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | AUNA | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -18.3x | -14.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | 2.0x | EPS est. 2.63 | Discount |
| Price / Book | 0.7x | 1.6x | Discount |
| Price / Sales | 0.3x | 0.5x | Discount |
| EV / EBITDA | 6.4x | 10.8x | Discount |
| Return on equity | 0.9% | — | Weak |
| Gross margin | 36.9% | 37.2% | In line |
| Debt / Equity | 2.01 | 2.76 | Levered |
| Piotroski / Altman Z | 6/9 | Z 0.93 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 29, 26 | Zamora Leon Jesus | director, officer: President | P-Purchase | 6,420 @ $4.15 | $26.64K |
| May 28, 26 |
| Zamora Leon Jesus |
| director, officer: President |
| P-Purchase |
| 9,220 @ $4.17 |
| $38.45K |
| May 26, 26 | Zamora Leon Jesus | director, officer: President | P-Purchase | 30,000 @ $4.39 | $131.7K |
| May 20, 26 | Zamora Leon Jesus | director, officer: President | P-Purchase | 5,814 @ $4.39 | $25.52K |
| May 28, 26 | Wilton John | director | S-Sale | 17,574 @ $4.17 | $73.30K |
| Mar 18, 26 | Zamora Leon Jesus | director, officer: President | 0 | — |
| May 27, 26 | Zamora Leon Jesus | director, officer: President | P-Purchase | 23,273 @ $4.20 | $97.70K |
| May 26, 26 | Zamora Leon Jesus | director, officer: President | P-Purchase | 8,727 @ $4.24 | $36.99K |
Stock news · updated daily
Auna NYSE: AUNA outlined its strategy for expanding an integrated healthcare platform across Latin America at its 2026 Investor Day, while also lowering expectations for adjusted EBITDA growth this year due to reimbursement and contracting pressures in Colombia.
Auna S.A. (AUNA) Analyst/Investor Day Transcript
LUXEMBOURG--(BUSINESS WIRE)--Auna S.A. (“Auna” or the “Company”) (NYSE: AUNA), a Latin American healthcare company with operations in Mexico, Peru and Colombia, announced today a preliminary update to its full-year 2026 outlook. Consistent with the recently disclosed operating KPIs that reflect favorable volume and specialty service trends in the third-quarter of 2026, the Company expects full-year 2026 revenue growth to be in line with the guidance communicated early in the year. The revenue g.
LUXEMBOURG--(BUSINESS WIRE)--Auna S.A. (“Auna” or the “Company”), a leading healthcare services platform in Latin America with operations in Mexico, Peru and Colombia, today announced the fulfillment of all conditions precedent to the commencement of construction under its Public-Private Partnership (“PPP”) agreement with EsSalud, Peru's Social Health Insurance agency. Following formal confirmation from EsSalud, the Centro Ambulatorio Trecca project will enter its investment and construction ph.
Auna's preliminary Q3 results showed stronger hospital activity across Peru, Colombia, and Mexico, with surgeries up 11.7% year-over-year. Higher hospital occupancy, expansion of oncology services, and contractual price adjustments support our expectations for an EBITDA margin to recover in H2 2026. Auna trades at approximately 4.5x forward EV/EBITDA, below its historical average, while improving FCF could support further deleveraging.
LUXEMBOURG--(BUSINESS WIRE)--Auna S.A. (“Auna” or the “Company”), a leading healthcare services platform in Latin America with operations in Mexico, Peru, and Colombia, today reported select operating metrics for the Third Quarter ended September 30, 2026. The Company publishes these key performance indicators on a quarterly basis as part of its commitment to providing investors with more information and a clearer understanding of Auna. Healthcare Services Mexico Key Operating Metri.
LUXEMBOURG--(BUSINESS WIRE)--Auna S.A. (NYSE: AUNA) (“Auna” or “the Company”), a leading Latin American healthcare services and plan provider with operations in Mexico, Peru and Colombia, announced today the reporting dates for its Third Quarter 2026 financial results. Earnings Release Tuesday, November 17, 2026 Time: After Market Close Conference Call Wednesday, November 18, 2026 Time: 8:00 a.m. ET Quiet Period Monday, November 2 through Tuesday November 17, 2026 To participate, please dial +1.
LUXEMBOURG--(BUSINESS WIRE)--Auna (NYSE: AUNA) (“Auna” or the “Company”), a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today that it will host its first Investor Day on Thursday, October 22, 2026. The event will be held in a hybrid format, offering both in-person attendance in Lima, Peru and a live webcast.On-site registration and networking breakfast with management will begin at 9:00 a.m. ET. Management presentations and the live webca.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 18, 2026 | 0.26 | 0.15 | Miss -43.1% | $362.6M |
| May 19, 2026 | 0.19 | 0.05 | Miss -73.7% | $336.4M |
| Mar 10, 2026 | 0.13 | 0.53 | Beat 307.7% | $336.7M |
| Nov 20, 2025 | 0.15 | 0.20 | Beat 33.3% | $316.1M |
| Aug 19, 2025 | 0.13 | 0.33 | Beat 153.8% | $308.4M |
| May 20, 2025 | 0.10 | 0.19 | Beat 90.0% | $1.04B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 6-K | Oct 22, 2026 | 2026-10-22 08:18:30 | View |
| SC 13G/A | Oct 8, 2026 | 2026-10-08 08:19:32 | View |
| 6-K | Aug 18, 2026 | 2026-08-18 17:12:52 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 13:51:17 | View |
| 6-K | Jul 15, 2026 | 2026-07-15 17:27:30 | View |
| SC 13G/A | Jul 9, 2026 | 2026-07-09 13:28:01 | View |
| 6-K | Jul 7, 2026 | 2026-07-07 17:16:24 | View |
| 4 | Jun 1, 2026 | 2026-06-01 20:48:06 | View |
| 4 | Jun 1, 2026 | 2026-06-01 20:46:04 | View |
| 3/A | Jun 1, 2026 | 2026-06-01 17:03:47 | View |
Proxy statement (DEF 14A) disclosures